Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia

(2009) Biren Saraiya et al.   ANTI-CANCER DRUGS

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

(2009) M. Breuleux et al.   MOLECULAR CANCER THERAPEUTICS

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody

(2008) L. Cao et al.   CANCER RESEARCH

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

mTOR—What Does It Do?

(2008) M.N. Hall   TRANSPLANTATION PROCEEDINGS

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER